Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis […]readmore
Tags : AC Immune
Shots: The P-II Lauriet study evaluates the safety & efficacy of semorinemab (anti-tau mAb) vs PBO in 272 adult patients with AD across 43 centers globally. The therapy is being […]readmore
Shots: The P-II TAURIEL study involves assessing of semorinemab vs PBO in 457 patients with early AD across 97 sites Genentech divulges that the P-II TAURIEL study did not meet […]readmore
Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes […]readmore